Europe
There was a little bit of positive COVID-19 news to report today. Here’s a look.
The Russian government is attempting to cast a negative light on the COVID-19 vaccine developed by Pfizer and BioNTech, as well as other vaccines, in order to boost sales of its own vaccine, Sputnik V, the government charged.
Roche announced it was voluntarily withdrawing the U.S. indication Tecentriq for in prior-platinum treated metastatic urothelial carcinoma (mUC) after failing to meet endpoints in confirmatory trials.
Merck KGaA is consolidating its Silicon Valley business/technology and materials innovations facilities under one 30,000-square-foot roof in San Jose, California, in an effort to boost their collaborative capacity for developing materials with biological applications.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
The study of VIR-7831, which is a dual-action SARS-CoV-2 monoclonal antibody, was recommended to be closed to enrollment by an independent data monitoring board, stating that “there were no reported safety signals, sensitivity analyses of the available data raised concerns about the magnitude of potential benefit.”
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 2, 2021.
Beijing-based CRMO Pharmaron has accomplished impressive global growth via acquisitions over the past eight months.
PRESS RELEASES